Qiweizhigan granule ameliorates metabolic dysfunction-associated steatohepatitis by modulating the galectin 3/tumor necrosis factor receptor-associated factor 6-mediated ferroptosis

Figure 1 Qiweizhigan granule ameliorated hepatic steatosis in metabolic dysfunction-associated steatohepatitis mice. A: Experimental design of Qiweizhigan granule animal trial; B: Body weight; C: Liver weight; D: Liver index (liver weight/body weight %); E: Liver total cholesterol content; F: Liver triglycerides content; G: Representative images of hematoxylin and eosin staining staining and Oil Red O staining; H-K: Histopathological scoring: Steatosis score, inflammation score, ballooning score, and NAFLD activity score were shown. Data were presented as means ± SEM. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. CDAHFD: Choline-deficient, L-amino acid-defined high-fat diet; HE: Hematoxylin and eosin; NAS: NAFLD activity score; QWZG: Qiweizhigan granule; RSG: Receiving rosiglitazone; TC: Total cholesterol; TG: Triglycerides.